Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
J Vet Diagn Invest
; 14(5): 389-95, 2002 Sep.
Article
em En
| MEDLINE
| ID: mdl-12296390
ABSTRACT
Tilmicosin is a novel macrolide antibiotic developed for exclusive use in veterinary medicine. Tilmicosin has been approved as a feed premix to control porcine respiratory disease associated with Pasteurella multocida and Actinobacillus pleuropneumoniae. The development of antimicrobial susceptibility testing guidelines for tilmicosin was predicated on the relationship of clinical efficacy studies that demonstrated a favorable therapeutic outcome, on pharmacokinetic data, and on in vitro test data, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS). The approved breakpoints for the minimum inhibitory concentration dilution testing for both species are resistant, > or = 32 microg/ml, and susceptible, < or = 16 microg/ml. The zone of inhibition interpretive criteria for disk diffusion testing with a 15-microg tilmicosin disk are resistant, < or = 10 mm, and susceptible, > or = 11 mm.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Pasteurella
/
Doenças dos Suínos
/
Infecções por Actinobacillus
/
Tilosina
/
Pasteurella multocida
/
Actinobacillus pleuropneumoniae
/
Macrolídeos
/
Antibacterianos
Tipo de estudo:
Guideline
/
Risk_factors_studies
Limite:
Animals
Idioma:
En
Revista:
J Vet Diagn Invest
Assunto da revista:
MEDICINA VETERINARIA
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Estados Unidos